Document Detail

Molecular Diagnostics of Lung Cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: Technology in Rapid Evolution.
MedLine Citation:
PMID:  23020723     Owner:  NLM     Status:  In-Data-Review    
The past 9 years have seen a remarkable shift in the diagnostic and therapeutic approach to lung carcinomas, beginning with the discovery of EGFR mutations and their role in directing management with targeted tyrosine kinase inhibitors. This special review recounts the experiences at one molecular diagnostic testing center, the Brigham and Women's Hospital/Dana-Farber Cancer Institute, from the initial research observations in 2003 to the development of multigene next-generation sequencing in 2012. Throughout this time, the activities in the molecular diagnostics laboratory have been in a state of rapid flux, responding to changes in clinical needs and scientific discoveries.
Neal Lindeman
Related Documents :
21358753 - Presence of tumoural c-reactive protein correlates with progressive prostate cancer.
24661213 - Strategic sirna screening approaches to target cancer at the cancer research uk beatson...
12239423 - Photochemoprevention by botanical antioxidants.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1198-200     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dilemmas in lung cancer staging.
Next Document:  Treatment of ALK-Positive Non-Small Cell Lung Cancer.